Cargando…

Improved therapy for neuroblastoma using a combination approach: superior efficacy with vismodegib and topotecan

Aberrant activation/expression of pathways/molecules including NF-kB, mTOR, hedgehog and polo-like-kinase-1 (PLK1) are correlated with poor-prognosis neuroblastoma. Therefore, to identify a most efficacious treatment for neuroblastoma, we investigated the efficacy of NF-kB/mTOR dual-inhibitor 13-197...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chaturvedi, Nagendra K., McGuire, Timothy R., Coulter, Don W., Shukla, Ashima, McIntyre, Erin M., Sharp, John Graham, Joshi, Shantaram S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924781/ https://www.ncbi.nlm.nih.gov/pubmed/26934655 http://dx.doi.org/10.18632/oncotarget.7714

Ejemplares similares

Treatment of a chemoresistant neuroblastoma cell line with the antimalarial ozonide OZ513
por: Coulter, Don W., et al.
Publicado: (2016)

Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma
por: Kling, Matthew J., et al.
Publicado: (2021)

Exosomes secreted under hypoxia enhance stemness in Ewing’s sarcoma through miR-210 delivery
por: Kling, Matthew J., et al.
Publicado: (2020)

Improved therapy for medulloblastoma: targeting hedgehog and PI3K-mTOR signaling pathways in combination with chemotherapy
por: Chaturvedi, Nagendra K., et al.
Publicado: (2018)

Long non-coding RNA profiling of pediatric Medulloblastoma
por: Kesherwani, Varun, et al.
Publicado: (2020)

Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma
por: Chaturvedi, Nagendra K., et al.
Publicado: (2019)

A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma
por: Kling, Matthew J., et al.
Publicado: (2022)

Effects of novel pyrrolomycin MP1 in MYCN amplified chemoresistant neuroblastoma cell lines alone and combined with temsirolimus
por: McGuire, Timothy R., et al.
Publicado: (2019)

Optimization of liposomal topotecan for use in treating neuroblastoma
por: Chernov, Lina, et al.
Publicado: (2017)

Interferon regulatory factor 4 attenuates Notch signaling to suppress the development of chronic lymphocytic leukemia
por: Shukla, Vipul, et al.
Publicado: (2016)

Activation of AMPK sensitizes medulloblastoma to Vismodegib and overcomes Vismodegib‐resistance
por: Gampala, Silpa, et al.
Publicado: (2021)

Amino Acids Regulate Cisplatin Insensitivity in Neuroblastoma
por: Gunda, Venugopal, et al.
Publicado: (2020)

An evaluation in vitro of the efficacy of nutlin-3 and topotecan in combination with (177)Lu-DOTATATE for the treatment of neuroblastoma
por: Tesson, Mathias, et al.
Publicado: (2018)

The dawn of hedgehog inhibitors: Vismodegib
por: Sandhiya, Selvarajan, et al.
Publicado: (2013)

Pilomatricomas secondary to treatment with vismodegib
por: Magdaleno-Tapial, Jorge, et al.
Publicado: (2018)

Experimental validation of predicted subcellular localizations of human proteins
por: Chaturvedi, Nagendra K, et al.
Publicado: (2014)

STAT3 Inhibition Attenuates MYC Expression by Modulating Co-Activator Recruitment and Suppresses Medulloblastoma Tumor Growth by Augmenting Cisplatin Efficacy In Vivo
por: Rohrer, Kyle A., et al.
Publicado: (2023)

A case of hepatotoxicity associated with vismodegib
por: Ly, Priscilla, et al.
Publicado: (2018)

Rare bone toxicity associated with vismodegib
por: Ciciarelli, Valeria, et al.
Publicado: (2020)

Inhalation delivery of topotecan is superior to intravenous exposure for suppressing lung cancer in a preclinical model
por: Kuehl, Philip J., et al.
Publicado: (2018)

Synthetic Lethal Screen Identifies NF-κB as a Target for Combination Therapy with Topotecan for patients with Neuroblastoma
por: Tsang, Patricia S, et al.
Publicado: (2012)

Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence
por: Taschner-Mandl, Sabine, et al.
Publicado: (2015)

Commentary: Periocular topotecan for retinoblastoma
por: Sharma, Minal, et al.
Publicado: (2018)

Vismodegib: the Proof of Concept in Basal Cell Carcinoma
por: Berrada, Narjiss, et al.
Publicado: (2014)

Metronomic Chemotherapy Based on Topotecan or Topotecan and Cyclophosphamide Combination (CyTo) in Advanced, Pretreated Ovarian Cancer
por: Wysocki, Piotr J., et al.
Publicado: (2023)

A chemical screen identifies the chemotherapeutic drug topotecan as a specific inhibitor of the B-MYB/MYCN axis in neuroblastoma
por: Sottile, Francesco, et al.
Publicado: (2012)

Venetoclax plus cyclophosphamide and topotecan in heavily pre-treated relapsed metastatic neuroblastoma: a single center case series
por: De Ioris, Maria Antonietta, et al.
Publicado: (2023)

Semi‐Mechanism‐Based Population Pharmacokinetic Modeling of the Hedgehog Pathway Inhibitor Vismodegib
por: Lu, T, et al.
Publicado: (2015)

Oral Metronomic Topotecan Sensitizes Crizotinib Antitumor Activity in ALK(F1174L) Drug-Resistant Neuroblastoma Preclinical Models()
por: Zhang, Libo, et al.
Publicado: (2017)

Topotecan and Cyclophosphamide in Adults with Relapsed Sarcoma
por: Blanchette, P., et al.
Publicado: (2012)

Periocular topotecan for vitreous seeds in retinoblastoma
por: Sthapit, Purnima R, et al.
Publicado: (2018)

Medical marijuana for the treatment of vismodegib-related muscle spasm
por: Yuan, Joyce T., et al.
Publicado: (2017)

Clues to primary vismodegib resistance lie in histology and genetics
por: Sun, Qisi, et al.
Publicado: (2020)

Treatment of periocular basal cell carcinoma with neoadjuvant vismodegib
por: Su, Maxwell G., et al.
Publicado: (2020)

Treatment of Locally Advanced Basal Cell Carcinomas with Vismodegib
por: Mastronardi, Luis, et al.
Publicado: (2021)

Vismodegib in Locally Advanced Basal Cell Carcinoma in Slovenia
por: Mesti, Tanja, et al.
Publicado: (2022)

miR-15a and miR-15b modulate natural killer and CD8(+)T-cell activation and anti-tumor immune response by targeting PD-L1 in neuroblastoma
por: Pathania, Anup S., et al.
Publicado: (2022)

Targeted Therapy for Advanced Basal-Cell Carcinoma: Vismodegib and Beyond
por: Cowey, C. Lance
Publicado: (2013)

Investigational agents in metastatic basal cell carcinoma: focus on vismodegib
por: Batty, Nicolas, et al.
Publicado: (2012)

Basal cell carcinoma: multimodal treatment and the role of neoadjuvant vismodegib
por: Martins, Pedro Carvalho, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kmhtspn16k9nk3igt2nso4q08g